BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

920 related articles for article (PubMed ID: 26627013)

  • 41. Learning from mouse models of MLL fusion gene-driven acute leukemia.
    Schwaller J
    Biochim Biophys Acta Gene Regul Mech; 2020 Aug; 1863(8):194550. PubMed ID: 32320749
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Requirement for CDK6 in MLL-rearranged acute myeloid leukemia.
    Placke T; Faber K; Nonami A; Putwain SL; Salih HR; Heidel FH; Krämer A; Root DE; Barbie DA; Krivtsov AV; Armstrong SA; Hahn WC; Huntly BJ; Sykes SM; Milsom MD; Scholl C; Fröhling S
    Blood; 2014 Jul; 124(1):13-23. PubMed ID: 24764564
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia.
    Jiang X; Huang H; Li Z; He C; Li Y; Chen P; Gurbuxani S; Arnovitz S; Hong GM; Price C; Ren H; Kunjamma RB; Neilly MB; Salat J; Wunderlich M; Slany RK; Zhang Y; Larson RA; Le Beau MM; Mulloy JC; Rowley JD; Chen J
    Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19397-402. PubMed ID: 23132946
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MLL-rearranged acute myeloid leukemia: Influence of the genetic partner in allo-HSCT response and prognostic factor of MLL 3' region mRNA expression.
    Burillo-Sanz S; Morales-Camacho RM; Caballero-Velázquez T; Carrillo E; Sánchez J; Pérez-López O; Pérez de Soto I; González Campos J; Prats-Martín C; Bernal R; Vargas MT
    Eur J Haematol; 2018 May; 100(5):436-443. PubMed ID: 29384595
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ALOX5 exhibits anti-tumor and drug-sensitizing effects in MLL-rearranged leukemia.
    Wang Y; Skibbe JR; Hu C; Dong L; Ferchen K; Su R; Li C; Huang H; Weng H; Huang H; Qin X; Jin J; Chen J; Jiang X
    Sci Rep; 2017 May; 7(1):1853. PubMed ID: 28500307
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sensitivity of MLL-rearranged AML cells to all-trans retinoic acid is associated with the level of H3K4me2 in the RARα promoter region.
    Sakamoto K; Imamura T; Yano M; Yoshida H; Fujiki A; Hirashima Y; Hosoi H
    Blood Cancer J; 2014 Apr; 4(4):e205. PubMed ID: 24769646
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The AAA+ ATPase RUVBL2 is a critical mediator of MLL-AF9 oncogenesis.
    Osaki H; Walf-Vorderwülbecke V; Mangolini M; Zhao L; Horton SJ; Morrone G; Schuringa JJ; de Boer J; Williams O
    Leukemia; 2013 Jul; 27(7):1461-8. PubMed ID: 23403462
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mouse models of MLL leukemia: recapitulating the human disease.
    Milne TA
    Blood; 2017 Apr; 129(16):2217-2223. PubMed ID: 28179274
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cell of origin determines clinically relevant subtypes of MLL-rearranged AML.
    Krivtsov AV; Figueroa ME; Sinha AU; Stubbs MC; Feng Z; Valk PJ; Delwel R; Döhner K; Bullinger L; Kung AL; Melnick AM; Armstrong SA
    Leukemia; 2013 Apr; 27(4):852-60. PubMed ID: 23235717
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Id2 and E Proteins Orchestrate the Initiation and Maintenance of MLL-Rearranged Acute Myeloid Leukemia.
    Ghisi M; Kats L; Masson F; Li J; Kratina T; Vidacs E; Gilan O; Doyle MA; Newbold A; Bolden JE; Fairfax KA; de Graaf CA; Firth M; Zuber J; Dickins RA; Corcoran LM; Dawson MA; Belz GT; Johnstone RW
    Cancer Cell; 2016 Jul; 30(1):59-74. PubMed ID: 27374225
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.
    Deshpande AJ; Chen L; Fazio M; Sinha AU; Bernt KM; Banka D; Dias S; Chang J; Olhava EJ; Daigle SR; Richon VM; Pollock RM; Armstrong SA
    Blood; 2013 Mar; 121(13):2533-41. PubMed ID: 23361907
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeting epigenetic programs in MLL-rearranged leukemias.
    Bernt KM; Armstrong SA
    Hematology Am Soc Hematol Educ Program; 2011; 2011():354-60. PubMed ID: 22160057
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The CDK4/6-UCHL5-BRD4 axis confers resistance to BET inhibitors in MLL-rearranged leukemia cells by suppressing BRD4 protein degradation.
    Amari K; Sasagawa S; Imayoshi N; Toda Y; Hosogi S; Imamura T; Ashihara E
    Biochem Biophys Res Commun; 2022 Jan; 588():147-153. PubMed ID: 34954522
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MLL-ENL-mediated leukemia initiation at the interface of lymphoid commitment.
    Ugale A; Säwén P; Dudenhöffer-Pfeifer M; Wahlestedt M; Norddahl GL; Bryder D
    Oncogene; 2017 Jun; 36(22):3207-3212. PubMed ID: 28068328
    [TBL] [Abstract][Full Text] [Related]  

  • 55. DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy.
    Liu W; Deng L; Song Y; Redell M
    PLoS One; 2014; 9(5):e98270. PubMed ID: 24858818
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CN470 is a BET/CBP/p300 multi-bromodomain inhibitor and has an anti-tumor activity against MLL-rearranged acute lymphoblastic leukemia.
    Imayoshi N; Yoshioka M; Tanaka K; Yang SM; Akahane K; Toda Y; Hosogi S; Inukai T; Okada S; Maloney DJ; Nakahata T; Takita J; Kato I; Ashihara E
    Biochem Biophys Res Commun; 2022 Jan; 590():49-54. PubMed ID: 34971957
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Complete molecular remission in relapsed and refractory acute myeloid leukaemia with MLL-AF9 treated with chidamide-based chemotherapy.
    Lun Y; Yang JJ; Wu Y
    J Clin Pharm Ther; 2017 Dec; 42(6):786-789. PubMed ID: 28646565
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MBNL1 regulates essential alternative RNA splicing patterns in MLL-rearranged leukemia.
    Itskovich SS; Gurunathan A; Clark J; Burwinkel M; Wunderlich M; Berger MR; Kulkarni A; Chetal K; Venkatasubramanian M; Salomonis N; Kumar AR; Lee LH
    Nat Commun; 2020 May; 11(1):2369. PubMed ID: 32398749
    [TBL] [Abstract][Full Text] [Related]  

  • 59. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
    Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
    Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models.
    Minzel W; Venkatachalam A; Fink A; Hung E; Brachya G; Burstain I; Shaham M; Rivlin A; Omer I; Zinger A; Elias S; Winter E; Erdman PE; Sullivan RW; Fung L; Mercurio F; Li D; Vacca J; Kaushansky N; Shlush L; Oren M; Levine R; Pikarsky E; Snir-Alkalay I; Ben-Neriah Y
    Cell; 2018 Sep; 175(1):171-185.e25. PubMed ID: 30146162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.